JP2015526395A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526395A5
JP2015526395A5 JP2015518523A JP2015518523A JP2015526395A5 JP 2015526395 A5 JP2015526395 A5 JP 2015526395A5 JP 2015518523 A JP2015518523 A JP 2015518523A JP 2015518523 A JP2015518523 A JP 2015518523A JP 2015526395 A5 JP2015526395 A5 JP 2015526395A5
Authority
JP
Japan
Prior art keywords
triazolo
pyrido
methyl
methoxybenzyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518523A
Other languages
English (en)
Japanese (ja)
Other versions
JP6129960B2 (ja
JP2015526395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/046415 external-priority patent/WO2013192229A1/en
Publication of JP2015526395A publication Critical patent/JP2015526395A/ja
Publication of JP2015526395A5 publication Critical patent/JP2015526395A5/ja
Application granted granted Critical
Publication of JP6129960B2 publication Critical patent/JP6129960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518523A 2012-06-18 2013-06-18 置換ピリジンアゾロピリミジン−5−(6h)−オン化合物 Active JP6129960B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
PCT/US2013/046415 WO2013192229A1 (en) 2012-06-18 2013-06-18 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017078803A Division JP6420400B2 (ja) 2017-04-12 2017-04-12 置換ピリジンアゾロピリミジン−5−(6h)−オン化合物

Publications (3)

Publication Number Publication Date
JP2015526395A JP2015526395A (ja) 2015-09-10
JP2015526395A5 true JP2015526395A5 (enExample) 2016-08-04
JP6129960B2 JP6129960B2 (ja) 2017-05-17

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518522A Active JP6240180B2 (ja) 2012-06-18 2013-06-18 置換チオフェン−およびフラン−縮合アゾロピリミジン−5−(6h)−オン化合物
JP2015518523A Active JP6129960B2 (ja) 2012-06-18 2013-06-18 置換ピリジンアゾロピリミジン−5−(6h)−オン化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015518522A Active JP6240180B2 (ja) 2012-06-18 2013-06-18 置換チオフェン−およびフラン−縮合アゾロピリミジン−5−(6h)−オン化合物

Country Status (17)

Country Link
US (7) US9175010B2 (enExample)
EP (3) EP2861605B1 (enExample)
JP (2) JP6240180B2 (enExample)
KR (2) KR102191816B1 (enExample)
CN (2) CN104583213B (enExample)
AU (3) AU2013277294C1 (enExample)
BR (2) BR112014031731B1 (enExample)
CA (2) CA2877146C (enExample)
DK (2) DK2861603T3 (enExample)
ES (2) ES2904267T3 (enExample)
IL (2) IL236232A (enExample)
IN (2) IN2015DN00335A (enExample)
MX (2) MX359615B (enExample)
NZ (2) NZ703950A (enExample)
RU (2) RU2653054C2 (enExample)
SG (3) SG11201408397SA (enExample)
WO (2) WO2013192229A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373540T3 (es) * 2000-08-10 2012-02-06 Cold Spring Harbor Laboratory Entrenamiento cognitivo aumentado.
AU2013277294C1 (en) 2012-06-18 2018-02-08 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
TWI609870B (zh) * 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) * 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
KR20190077349A (ko) 2016-10-28 2019-07-03 하. 룬드벡 아크티에셀스카브 이미다조피라지논의 투여를 포함하는 병용 치료
EP3532064B1 (en) 2016-10-28 2020-07-29 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
CN110392686A (zh) * 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
EP3585392A1 (en) * 2017-02-23 2020-01-01 Boehringer Ingelheim International GmbH New medical use of compound iii
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
TW201920188A (zh) 2017-08-10 2019-06-01 美商美國禮來大藥廠 [1,2,4]三唑衍生物
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Pde1阻害剤としての置換フラノピリミジン化合物
SG11202009735QA (en) 2018-04-13 2020-10-29 Cancer Research Tech Ltd Bcl6 inhibitors
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
EP3908285A4 (en) 2019-01-07 2022-10-19 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2021035157A1 (en) * 2019-08-22 2021-02-25 Intra-Cellular Therapies, Inc. Organic compounds
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (en) * 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
WO2025024543A1 (en) * 2023-07-24 2025-01-30 Bpgbio, Inc. Tricyclic ube2k modulators and methods for their use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ− アクチエンゲゼルシヤフト 2−置換−e−融合−〔1,2,4〕トリアゾロ−〔1,5−C〕ピリミジン
DE3677445D1 (de) 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) * 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
EP1051167A1 (en) * 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
ES2373540T3 (es) 2000-08-10 2012-02-06 Cold Spring Harbor Laboratory Entrenamiento cognitivo aumentado.
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
WO2007143705A2 (en) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
US20090053140A1 (en) 2007-05-15 2009-02-26 Roderick Euan Milne Scott METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
US20100203624A1 (en) 2007-09-26 2010-08-12 Ge Healthcare Bioscience Bioprocess Corp. Three dimensional disposable bioreactor
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
AU2013277294C1 (en) * 2012-06-18 2018-02-08 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Similar Documents

Publication Publication Date Title
JP2015526395A5 (enExample)
RU2015100213A (ru) Замещенные соединения пиридин азолопиримидин-5-(6н)-она
JP2015526394A5 (enExample)
AU2022328206A1 (en) Heterocyclic compounds and methods of use
WO2024076672A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
AU2024266099A1 (en) Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
JP2014506929A5 (enExample)
JP2012505895A5 (enExample)
IL275344B2 (en) 4-azaindole compounds
JP2014534976A5 (enExample)
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
IL277579B (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
JP2017505327A5 (enExample)
JP2023545545A (ja) 複素環スピロ化合物及び使用方法
HRP20150882T1 (hr) Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
HRP20200556T1 (hr) Novi (hetero) aril-supstituirani-piperidinil derivati, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
RU2018105684A (ru) Замещенные трициклические соединения и способ применения
HRP20230120T1 (hr) Inhibitori bcl6
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
JP2018514552A5 (enExample)
HRP20191180T1 (hr) Imidazopirazinoni kao inhibitori pde1
HRP20160649T1 (hr) Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba
RU2015143536A (ru) Новые соединения в качестве ингибитора фосфодиэстеразы типа 10а
RU2019109039A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
JPWO2019197842A5 (enExample)